CG
IMVT icon

Cutler Group’s Immunovant IMVT Stock Holding History

Cutler Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$64K Buy
+2,000
New +$73K 0.02% 579
2023
Q4 		– Sell
-900
Closed -$33.1K – 3936
2023
Q3 		$34K Buy
+900
New +$20.3K ﹤0.01% 1700

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Cutler Group's IMVT Position: Q1 2024 in Review

Cutler Group opened a new position in Immunovant (IMVT) in Q1 2024: 2,000 shares worth $64K. The stake represents 0.02% of the portfolio and ranks #579 among its holdings. This is a return to the name: Cutler Group previously reported a position in IMVT as recently as Q3 2023.

Cutler Group first reported a position in IMVT in Q3 2023 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Cutler Group held 2,000 shares of Immunovant worth $64K as of Q1 2024.
  • Immunovant was a new Cutler Group position in Q1 2024.
  • Immunovant made up 0.02% of Cutler Group's portfolio in Q1 2024, its #579 holding.
  • Cutler Group first reported a position in Immunovant in Q3 2023 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.